A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Summary

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Timeline

Start

2024-04-11

Primary completion

2026-06

Completion

2026-12

Outcome

Met primary endpoint

release “CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM demonstrated robust left ventricular outflow tract (LVOT) gradient reductions without meaningful changes in LVEF” edgewisetx.com ↗

release “today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM” edgewisetx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EDG-7500	Unknown	—	Oral

Indications